Skip to Main Content

You remember Martin Shkreli. He rocketed to notoriety three years ago when the company he ran, Turing Pharmaceuticals, bought an old anti-infective drug used by AIDS patients and quickly boosted the price of a tablet to $750 from $13.55.  He was widely derided by the pharmaceutical industry as an outlier, although many other companies have regularly trafficked in such maneuvers.

A new analysis, however, suggests these moves are even more common than imagined.


A group of researchers examined a few dozen older drugs that no longer had patent protection but had changed hands, and they found the median price more than doubled after acquisition.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!